Evidence map›Paper›PMID 32313567›Full record

ArticleTherapeutic advances in medical oncology2020

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.

David W Doo, Selene Meza-Perez, Angelina I Londoño, Whitney N Goldsberry, Ashwini A Katre, Jonathan D Boone, Dylana J Moore, Cindy T Hudson, Ilaria Betella, Tyler R McCaw and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Evolutionary conservation and cancer implications of the WNT signaling pathway.Medical oncology (Northwood, London, England) · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

David W DooDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Selene Meza-PerezDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Angelina I LondoñoDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Whitney N GoldsberryDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ashwini A KatreDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jonathan D BooneDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Dylana J MooreDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Cindy T HudsonDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ilaria BetellaComprehensive Cancer Center, University of Alabama at Birmingham, AL, USA.ORCID https://orcid.org/0000-0001-9191-8228
Tyler R McCawDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Abhishek GangradeDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Riyue BaoDepartment of Pediatrics, University of Chicago School of Medicine, Chicago, IL, USA.
Jason J LukeDepartment of Medicine, University of Chicago School of Medicine, Chicago, IL, USA.
Eddy S YangComprehensive Cancer Center, University of Alabama at Birmingham, AL, USA.
Michael J BirrerDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Dmytro StarenkiHudson Alpha Institute for Biotechnology, Huntsville, AL, USA.
Sara J CooperHudson Alpha Institute for Biotechnology, Huntsville, AL, USA.
Donald J BuchsbaumComprehensive Cancer Center, University of Alabama at Birmingham, AL, USA.
Lyse A NorianComprehensive Cancer Center, University of Alabama at Birmingham, AL, USA.
Troy D RandallDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Rebecca C ArendDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, 619 19th Street South, 176F Rm 10250, Birmingham, AL 35249, USA.
University of Alabama at Birmingham · USHudsonAlpha Institute for Biotechnology · USUniversity of Chicago · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Role of microbiota in therapy to ovarian cancerR01CA216234 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2017 to 2021
$2.1M
Research Training Program in Basic and Translational OncologyT32CA183926 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, RAVI · 2014 to 2018
$1.0M
NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA216234NCI NIH HHS T32 CA183926
6 · The paper itself

Abstract

backgroundThe Wnt/β-catenin pathway is linked to tumorigenesis in a variety of tumors and promotes T cell exclusion and resistance to checkpoint inhibitors. We sought to determine whether a small molecule inhibitor of this pathway, WNT974, would impair tumor growth, affect gene expression patterns, and improve the immune response in human and murine ovarian cancer models.

methodsHuman ovarian cancer cells were treated with WNT974

resultsGene expression profiling revealed distinct signatures in responders and nonresponders, which strongly correlated with T cell infiltration patterns in the TCGA analysis of ovarian cancer. WNT974 inhibited tumor growth, prevented ascites formation, and prolonged survival in mouse models. WNT974 increased the ratio of CD8

conclusionsThese findings suggest that inhibiting the Wnt/β-catenin pathway may have a potent immunomodulatory effect in the treatment of ovarian cancer, particularly when combined with paclitaxel.

Indexed as

cancer immunologyimmune checkpointsimmunotherapyovarian cancerpaclitaxeltumor immunityWnt/β-catenin pathway

Identifiers

PMID32313567
PMCPMC7158255
OpenAlexW3016290153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.